Chemotherapy – Page 4 – Medical News Asia

Plasma TMB predicts response to atezolizumab in NSCLC patients

31 August 2018/0 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Pathology, Translational Research/by scienterrific

A high tumour mutational burden in the plasma (bTMB) is a clinically actionable biomarker for atezolizumab (Tencentriq®, Roche) treatment in patients who failed 1st-line platinum-based therapy for advanced non-small cell lung cancer (NSCLC).

Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

19 August 2018/1 Comment/in Breast Cancer, Oncology, Chemotherapy, Targeted Therapies/by scienterrific

Single-agent PARP-inhibition with talazoparib is associated with an improved progression-free survival (PFS) and better patient-reported outcomes (PRO) when compared to chemotherapy alone in patients with advanced breast cancer (ABC) and a germline BRCA1/2 mutation, as reported by the investigators of the Phase III EMBRACA study (NCT01945775) in the New England Journal of Medicine.

FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL

9 August 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Oncology, Chemotherapy/by scienterrific

On the 8th of August 2018, the FDA approved mogamulizumab-kpkc (Poteligeo®, Kyowa Kirin), a CC chemokine receptor type 4 (CCR4) directed monoclonal antibody, for use in adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

30 July 2018/0 Comments/in Lung Cancer, Oncology, Chemotherapy, Targeted Therapies, Translational Research/by scienterrific

Osimertinib is active in the second-line treatment of patients with T790M-positive advanced non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, as reported by the investigators of the Phase III AURA3 study.

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

25 June 2018/5 Comments/in ASCO 2018 Annual Meeting, Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies/by Anne John Michael

Non-small cell lung cancer (NSCLC): a key feature of the American Society of Clinical Oncology (ASCO) 2018 annual meeting. This year, encouraging results with single-agent immunotherapy (I-O) and combinations of I-O with chemotherapy (CTx), including the CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 and KEYNOTE-407 studies with pembrolizumab (PEMBRO). Furthermore, important Asian data on treatments for epidermal growth-factor recptor (EGFR) mutation-positive (mu+) NSCLC (ARCHER 1050, NEJ009, NEJ026, and JO25567).

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

19 June 2018/2 Comments/in Breast Cancer, ASCO 2018 Annual Meeting, Conferences, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies, Translational Research/by Stijn van den Borne, MSc

Breast cancer: a front-runner when it comes to the development of novel therapeutic strategies. With the advent of newer targeted- and immunotherapies, oncologists have an increment of options to offer their patients. The American Society of Clinical Oncology’s (ASCO) 2018 Breast Cancer track offered an extensive look at the latest advancements and updates from on-going trials covering the various subtypes of breast cancer.

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

14 June 2018/0 Comments/in US FDA Onc\Haem Approvals, Gynaecological Cancer, Oncology, Chemotherapy, Targeted Therapies/by scienterrific

On June 13, 2018, the FDA approved bevacizumab (AvastinⓇ, Genentech, Inc.) in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab for use after surgical resection in patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

10 June 2018/5 Comments/in ASCO 2018 Annual Meeting, Gastrointestinal Cancer, Conferences, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies, Translational Research/by Anne John Michael

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

10 May 2018/4 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

First-line atezolizumab plus bevacizumab, carboplatin and paclitaxel improves PFS in patients with non-squamous NSCLC. Two presentations on the IMPower150 study by Martin Reck (ELCC 2018) and Mark Socinski (AACR 2018) discussed the frontline addition of atezolizumab to bevacizumab and chemotherapy in different lung cancer subgroups (NCT02366143).

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

21 April 2018/6 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

AACR 2018: First-line nivolumab-ipilimumab in TMB-high NSCLC with was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy in the Phase III CheckMate 227 trial (NCT02477826).